DTIL — Precision Biosciences Income Statement
0.000.00%
Last trade - 00:00- $81.33m
- $41.44m
- $68.70m
Annual income statement for Precision Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 24.3 | 116 | 25.1 | 48.7 | 68.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 134 | 149 | 98.3 | 92.5 | 94.9 |
| Operating Profit | -110 | -33.4 | -73.2 | -43.7 | -26.2 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -109 | -30.6 | -72.9 | -42.5 | 7.17 |
| Net Income After Taxes | -109 | -30.6 | -72.9 | -42.5 | 7.17 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -109 | -30.6 | -112 | -61.3 | 7.17 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -109 | -30.6 | -112 | -61.3 | 7.17 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -62.9 | -18.7 | -21.2 | -11 | 1.1 |